Narayana Hrudayalaya Ltd (NH) Q1 FY27 Earnings Call: Domestic Hospital EBITDA Grows 40% YoY, Cayman Insurance Repricing Achieves 100% Acceptance

Narayana Hrudayalaya Ltd held its Q1 FY27 earnings call on July 31, 2026. Here's a quick read of what management said — performance, strategy, and the outlook ahead.

Headline numbers across the portfolio

• Domestic hospital EBITDA grew 40% YoY in Q1 FY 2026-2027, driven by higher footfalls and realizations from high-end procedures and robotics, despite no bed additions in the last 7-8 years.
• Cayman insurance quarterly loss reduced to ~$3.7M in Q1 FY 2026-2027 from ~$5.2M in Q4 FY 2025-2026, with management believing the worst is behind them barring abnormal large claims.
• A-Loss came in at 4.3 in Q1 FY 2026-2027, with management targeting 3.9-4.0 as soon as possible.
• Clinic OP consults grew 30% YoY to ~66,000 in Q1 FY 2026-2027; two more clinics are being opened in Q2 FY 2026-2027.
• India clinics business reported a loss of approximately Rs.15 crores for Q1 FY 2026-2027.
• Consolidated EBITDA margin declined temporarily in Q1 FY 2026-2027, but India business net margin expanded 400 bps YoY; KIMS Hospital is at optimal margins.

Building a vertically integrated ecosystem

• Ownership of both insurance and care delivery provides a structural underwriting advantage for group policy pricing using clinical, diagnostic, pharmacy, and utilization data from the clinic network.
• Loss ratios spiked in Q1 FY 2026-2027 due to a few large claims on a small book; expense ratio improved. Management is implementing AI-based claims review, in-sourcing claims, and focusing on SME/retail business to moderate loss ratios over time.
• Cayman insurance July 2026 contract repricing achieved 100% acceptance with price increases to a more sustainable level; results will reflect in Q2 FY 2026-2027, and a similar outcome is expected in the January 2027 cycle.
• Underwriting profitability pursued via three levers in priority order: reducing operating expenses (significant drop already achieved), better risk selection, and responsible premium pricing.
• Management declined to provide a timeline for when the insurance business will contribute to profitability, citing the portfolio's current size and volatility.
• The insurance entity sits inside the listed company, suppressing consolidated return metrics; the board defined a maximum acceptable cumulative investment and period, with reassessment every few quarters.

Operating leverage without bed expansion

• Domestic hospital EBITDA grew 40% YoY in Q1 FY 2026-2027, driven by higher footfalls and realizations from high-end procedures and robotics, with no bed additions in the last 7-8 years.
• No meaningful bed additions planned for the next 2-3 years; management expects core operating margins to expand through operating leverage while balancing affordable-care philosophy and cash-flow reinvestment.
• Clinic network contributed 30% of total OPD footfalls in Q1 FY 2026-2027, driving referrals for high-end complex procedures.
• HSR hospital expansion is on track; North Bangalore is a priority for the second round of expansion (no specific timeline given).
• The 100-bed Southwest Bangalore project is on track to operationalize by end of Q2 FY 2026-2027.
• Minor delays in two asset-light projects due to partner licensing issues, pushing commissioning from FY 2027-2028 to FY 2028-2029 (two projects) and FY 2029-2030 (one project); resolution expected within a month.

Cayman momentum, UK turnaround underway

• Cayman hospitals reported ~6% USD revenue growth in Q1 FY 2026-2027 (described as a seasonal softer quarter), with discharges and outpatient footfall showing healthy double-digit YoY growth driven by the integrated care strategy.
• Cayman insurance annualized book is approximately $60 million; sequential margin pressure in Q1 vs. Q4 FY 2025-2026 was driven by seasonality.
• UK business revenue declined sequentially in Q1 FY 2026-2027, but YoY growth vs. pre-acquisition period was ~5%; growth was impacted by a widespread heat wave causing chiller/AC failures (expected to be a one-off event).
• UK business was 95% NHS-dependent at acquisition; management stated "the closest peer mix is ~70% NHS, which is the target, expected to take 4-5 years to achieve," with early signs of payer diversification encouraging.
• UK medical software deployment faces a 4-6 month regulatory delay due to reclassification as software-as-a-medical-device, described as a one-time effort that will create a competitive advantage.
• UK integration progressing well; separations from the erstwhile parent are complete, and transformation plan and software rollouts are underway.

Strong balance sheet, multi-year investment cycle

• Net debt-to-EBITDA remained less than 1x as of Q1 FY 2026-2027, with debt expected to increase over the next 2-3 years as project construction ramps; management stated "debt levels to be lower by FY30" (FY 2029-2030).
• Rs.3,000 crores committed for projects over the next two years (FY 2027-2028 and FY 2028-2029), with a mix of own contribution and borrowings.
• Cash balance increased from FY 2025-2026 year-end to Q1 FY 2026-2027, attributed entirely to operating performance of India and Cayman businesses.
• Professional fees jumped to Rs.327 crores in Q1 FY 2026-2027 from Rs.244 crores in Q4 FY 2025-2026, attributed solely to a reclassification entry; actual cost was flat QoQ.
• UK ROCE reporting expected to begin only after four quarters from the call date (not before Q1 FY 2027-2028); management did not provide a specific ROCE target for a 2030 milestone.
• Domestic expansion phase one focused on existing clusters over the next three financial years; management noted "phase two will consider new states like Uttar Pradesh and Bihar."